We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Improved EBV and CMV Assays

By HospiMedica staff writers
Posted on 08 Aug 2005
New versions of assays for the monitoring and treatment of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) feature improvements that provide highly accurate and reproducible sample testing and ease of use. More...
Both assays have received the CE Mark.

These ReSSQ assays are the products of LightUp Technologies AB (Huddinge, Sweden) and its distribution partner, DakoCytomation A/S (Glostrup, Denmark). The assays have been shown to be very robust and sensitive, and are validated for use in conjunction with several real-time polymerase chain reaction (PCR) platforms. The newly improved versions were presented at the International Herpesvirus Workshop (IHW) meeting in Turku (Finland) beginning on July 30, 2005.

"These enhanced products are the results of LightUp Technologies' continuous striving to improve and extend its product line, which is targeted towards clinical diagnostic laboratories for efficient, accurate, and cost-effective DNA detection and quantification of viral pathogens,” observed Ulrica Sehistedt, Ph.D., CEO and head of commercial operations at LightUp Technologies.

Geoff Gower, director of microbiology at DakoCytomation, added, "We are confident these improved CE-Marked products will meet customers' expectations and prove an important addition to our portfolio.” DakoCytomation has co-exclusive rights to market and sell LightUp's products in Europe.

Based on LightUp Technologies' proprietary diagnostic platform, the unique LightUp probe at the heart of the ReSSQ assays becomes fluorescent upon binding to the chosen target DNA and is designed to work with real-time PCR.





Related Links:
LightUp Technologies
DakoCytomation

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Tourniquet System
heidi– mein Tourniquet
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.